CTDSP1 inhibitor rabeprazole regulates DNA-PKcs dependent topoisomerase I degradation and irinotecan drug resistance in colorectal cancer

Irinotecan specifically targets topoisomerase I (topoI), and is used to treat various solid tumors, but only 13–32% of patients respond to the therapy. Now, it is understood that the rapid rate of topoI degradation in response to irinotecan causes irinotecan resistance. We have published that the de...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:PLoS One
Hauptverfasser: Matsuoka, Hiroya, Ando, Koji, Swayze, Emma J., Unan, Elizabeth C., Mathew, Joseph, Hu, Quingjiang, Tsuda, Yasuo, Nakashima, Yuichiro, Saeki, Hiroshi, Oki, Eiji, Bharti, Ajit K., Mori, Masaki
Format: Artigo
Sprache:Inglês
Veröffentlicht: Public Library of Science 2020
Schlagworte:
Research Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7413750/
https://ncbi.nlm.nih.gov/pubmed/32764831
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0228002
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge